Neoplastic Disease
2
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Telix PharmaceuticalsAustralia - Brisbane
2 programs1
1
TLX-101-Tx + LomustinePhase 31 trial
131I-IPAPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
2027
Telix PharmaceuticalsTLX-101-Tx + Lomustine
Telix Pharmaceuticals131I-IPA
Clinical Trials (2)
Total enrollment: 62 patients across 2 trials
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
Start: Nov 2025Est. completion: Nov 202750 patients
Phase 3Recruiting
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
Start: Apr 2023Est. completion: Jun 202612 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 62 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.